Last updated: 2026-09-17 22:06:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Alaunos Therapeutics, Inc. (TCRT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.61, with a market capitalization of $3.58M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.28 to $4.59. This page covers its latest market performance, valuation, price trends and company information.
$3.58M | |
$1.35 | |
$601.50 | |
$1.28 | |
$1.28 | |
100.24K | |
12.95K | |
-- | |
$4.59 | |
$1.28 | |
-- | |
-- |
Alaunos Therapeutics, Inc. (TCRT) is trading at $2.15 in after-hours trading as of 2026-09-17 22:05:00, up 67.66% ($0.87) from the regular-session close of $1.28.
After-hours trading shows how investors are pricing TCRT after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Alaunos Therapeutics, Inc. (TCRT) moved from $1.57 to $1.61, representing a gain of 2.80% ($0.04).
The stock traded between $1.28 and $1.63 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 17.04 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 10.1%
TCRT is currently trading at $1.61, placing it 10.1% of the way from its 52-week low of $1.28 to its 52-week high of $4.59. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alaunos Therapeutics, Inc. (TCRT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.